Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications
Conditions: Non-small Cell Lung Cancer; Non-Small Cell Lung Adenocarcinoma; Non-Small Cell Squamous Lung Cancer; Head and Neck Squamous Cell Carcinoma; Esophageal Cancer; Gastric Cancer; Breast Cancer; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Liposarcoma

Interventions: Drug: BBI-355; Drug: Erlotinib; Drug: Futibatinib

Sponsors: Boundless Bio

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 29, 2024Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments